Paris - Delayed Quote EUR

DBV Technologies S.A. (DBV.PA)

1.4880
+0.0100
+(0.68%)
At close: June 6 at 5:35:08 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Daniel Tassé CEO & Director 862.95k -- 1960
Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. Chief Financial Officer 354.67k -- 1969
Dr. Pharis Mohideen M.D. Chief Medical Officer 630.18k -- 1965
Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. Chief Operations Officer -- -- --
Ms. Michele F. Robertson Chief Legal Officer -- -- --
Ms. Caroline Daniere Chief Human Resources Officer & Chief of Staff -- -- 1974
Alan Kerr Senior VP & Head of Global Regulatory Affairs -- -- --
Mr. Pascal Wotling Chief External Manufacturing & Supply Chain Officer -- -- --
Dr. Robert G. Pietrusko Pharm. D., Pharm.D. Chief Regulatory Officer -- -- 1948
Katie Matthews Investor Relations Officer -- -- --

DBV Technologies S.A.

Bâtiment IRO
107 Av. de la République
Châtillon, 92320
France
33 1 55 42 78 78 https://www.dbv-technologies.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
106

Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Corporate Governance

DBV Technologies S.A.’s ISS Governance QualityScore as of June 1, 2025 is 10. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 1; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 28, 2025 at 10:59 AM UTC - August 1, 2025 at 12:00 PM UTC

DBV Technologies S.A. Earnings Date

Recent Events

Related Tickers